Thrive Capital led a $600m funding round in Isomorphic Labs.

Thrive Capital, an investment firm focusing on internet, software, and technology-enabled companies, led a $600m funding round in Isomorphic Labs, an AI-first drug discovery and development company, with participation from GV and Alphabet. "We're excited to bring together a top-tier investor group with deep AI and life sciences expertise as we aim to transform this industry through an interdisciplinary approach. This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI," Demis Hassabis, Isomorphic Labs Founder and CEO.